GlassScriptPhysician profile
Mohammed T Ijaz
NPI 1124189592
$48,913.67
in general payments reported to CMS, 2019-2025
19 companies · $1,984 in 2025
The $1,984 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $11K · 2021: $3,801 · 2022: $6,089 · 2023: $6,476 · 2024: $531 · 2025: $1,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,400 · Travel and Lodging: $1,882 · Food and Beverage: $1,676 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,400.00 |
| Travel and Lodging | $1,882.16 |
| Food and Beverage | $1,676.40 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30,926.40 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $11,961.61 | 2019-2025 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $2,069.86 | 2019 | |
| Medtronic, INC. | $1,151.99 | 2021-2025 | Minimed 780g, Inceptiv |
| Corcept Therapeutics | $1,023.47 | 2020-2025 | Korlym |
| Insulet Corporation | $553.07 | 2024-2025 | Omnipod |
| Novo Nordisk INC | $434.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic Minimed, INC. | $205.91 | 2019-2020 | |
| Sequel Med Tech, LLC | $139.49 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Farxiga |
| Shire North American Group INC | $109.19 | 2019 | |
| Abbott Laboratories | $61.75 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $55.45 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $18.69 | 2025 | Evenity |
| Acella Pharmaceuticals, LLC | $18.18 | 2025 | NP Thyroid 60 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $16.35 | 2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $16.20 | 2025 | Flector, Licart, Tirosint |
| Radius Health, INC. | $15.59 | 2025 | |
| Beta Bionics, INC. | $11.15 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ijaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.